Vishwesh Patil
Overview
Explore the profile of Vishwesh Patil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panwar R, Bhattarai P, Patil V, Gada K, Majewski S, Khaw B
J Nucl Cardiol
. 2018 Feb;
26(4):1327-1344.
PMID: 29392624
Background: Radiolabeled anti-myosin imaging is well-established for imaging doxorubicin-induced cardiotoxicity. However, to enable imaging of drug-induced cardiotoxicity in small experimental animals, pretargeting with bispecific anti-myosin-anti-DTPA-Fab-Fab' and targeting with high-specific radioactivity...
2.
Gada K, Patil V, Panwar R, Hatefi A, Khaw B
Drug Deliv Transl Res
. 2015 Mar;
2(1):65-76.
PMID: 25786600
The pretargeting approach using bispecific affibody-antibody complex (BAAC) and targeting of chemotherapeutic drug loaded polymers have been used in breast cancer cell cultures to demonstrate targeted chemotherapy and reduce toxicity...
3.
Khaw B, Gada K, Patil V, Panwar R, Mandapati S, Hatefi A, et al.
Eur J Nucl Med Mol Imaging
. 2014 Mar;
41(8):1603-16.
PMID: 24643779
Introduction: Doxorubicin, a frontline chemotherapeutic agent, limited by its cardiotoxicity and other tissue toxicities, was conjugated to N-terminal DTPA-modified polyglutamic acid (D-Dox-PGA) to produce polymer pro-drug conjugates. D-Dox-PGA or Tc-99...
4.
Patil V, Gada K, Panwar R, Majewski S, Tekabe Y, Varvarigou A, et al.
J Drug Target
. 2013 Jul;
21(10):1012-21.
PMID: 23863118
Background: Bombesin has been used to target Bombesin receptor, a growth receptor, which is over-expressed in many cancers, including prostate cancer. Polymer-anti-neoplastic-drug-conjugates (PDC) were also developed to reduce non-specific toxicity...
5.
Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, et al.
Eur J Nucl Med Mol Imaging
. 2012 Feb;
39(5):824-39.
PMID: 22302089
Purpose: Pretargeting with bispecific monoclonal antibodies (bsMAb) for tumor imaging was developed to enhance target to background activity ratios. Visualization of tumors was achieved by the delivery of mono- and...
6.
Gada K, Patil V, Panwar R, Majewski S, Tekabe Y, Khaw B
Nucl Med Commun
. 2011 Oct;
32(12):1231-40.
PMID: 22001720
Introduction: Bispecific monoclonal antibodies (bsMAbs) have been developed as a pretargeting tool to reduce background activity, thereby increasing target to background (T : B) ratios. To enhance visualization of small...
7.
Patil V, Khudairi T, Khaw B
Methods Mol Biol
. 2010 Jan;
605:305-20.
PMID: 20072890
Pathological conditions such as hypoxia and inflammation can lead to the development of cell membrane-lesions. The presence of these membrane-lesions leads to egress of intracellular macromolecules as well as exposure...
8.
Dandamudi S, Patil V, Fowle W, Khaw B, Campbell R
Cancer Sci
. 2009 May;
100(8):1537-43.
PMID: 19459849
The use of magnetic drug targeting (MDT) to selectively deliver chemotherapeutic drugs to tumor cells is a widely investigated approach; however, the notion of targeting tumor endothelial cells by this...